Harbour BioMed Public Relations
E-mail: pr@harbourbiomed.com
June 05, 2018
Collaboration combines Harbour’s proprietary H2L2 transgenic mouse platform for generating fully human monoclonal antibodies with Wistar’s cancer biology, immunology expertise
PHILADELPHIA, PA, CAMBRIDGE, MA and SHANGHAI, CHINA — June 4, 2018 —Harbour BioMed and The Wistar Institute announced today that they have entered into a multi-year, multifaceted research collaboration to co-discover novel antibodies for the treatment of cancer and infectious diseases.
This strategic collaboration will leverage Harbour BioMed’s innovative H2L2 platform with Wistar’s fundamental research expertise in cancer biology and immunology to generate fully human monoclonal antibodies directed against unique targets. Harbour BioMed and Wistar will work together to select targets, generate and validate novel antibodies against tumor and infectious antigens. This collaboration is a milestone-driven endeavor, with the collective goal of generating commercially viable therapeutic candidates. Financial terms were not disclosed.
“Combining Harbour BioMed’s next generation human antibody platform technology with Wistar’s core strengths in early stage research and discovery is an innovative industry-academia collaboration specifically designed to rapidly move attractive therapeutic candidates into the next phase of clinical development,” said Mai-Jing Liao, PhD, MBA, Senior Vice President, Business Development and Portfolio Management at Harbour BioMed. “We are pleased to be working with The Wistar Institute and look forward to opening new scientific avenues together.”
“Collaborating with the world’s leading academic institutions such as Wistar is an integral part of our strategy to build a truly innovative product portfolio at Harbour. Drug candidates derived from this exciting collaboration will enhance our ability to be competitive at the global level and to better fulfill unmet medical needs for patients worldwide,” said Jingsong Wang, MD, PhD, Chairman & CEO at Harbour BioMed.
“This partnership embodies Wistar’s philosophy of establishing collaborations that operate in the early stages of the discovery process in order to accelerate the advancement of the high-risk, high-reward preclinical drug discoveries,” said Heather Steinman, PhD, MBA, Vice President for Business Development and Executive Director of Technology Transfer at Wistar.
The agreement will support the research and development of numerous antibody discovery programs per year. Wistar and Harbour BioMed have established a joint steering committee to facilitate the advancement of simultaneous programs towards the end goal of moving new therapeutic candidates rapidly into the clinic. David B. Weiner, Ph.D., Executive Vice President and Director of the Vaccine & Immunotherapy Center at Wistar, will be playing an integral role in overseeing Wistar’s scientific efforts in the collaboration.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.
The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
For further information, please refer to www.harbourbiomed.com
About Wistar
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. Wistar’s Business Development Team is dedicated to advancing Wistar Science and Technology Development through creative partnerships. wistar.org.
Contact:
Timothy Miller
Harbour Antibodies
(857) 214-0976
timothy.miller@harbourbiomed.com
Darien Sutton
The Wistar Institute
(215) 898-3988
Harbour BioMed Public Relations
E-mail: pr@harbourbiomed.com